Ocular Therapeutix
OCUL
OCUL
184 hedge funds and large institutions have $1.45B invested in Ocular Therapeutix in 2025 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 75 increasing their positions, 48 reducing their positions, and 31 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
184
Holders Change
-12
Holders Change %
-6.12%
% of All Funds
2.47%
Holding in Top 10
10
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.13%
New
22
Increased
75
Reduced
48
Closed
31
Calls
$9.7M
Puts
$4.1M
Net Calls
+$5.6M
Net Calls Change
+$2.62M
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$173M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$19.5M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$12.5M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$6.81M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$5.85M |
Top Sellers
| 1 |
BlackRock
New York
|
-$13.6M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$12.2M |
| 3 |
PA
Perceptive Advisors
New York
|
-$6.71M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$6.12M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$4.04M |
